Europe Plasmapheresis Machine Market Size & Outlook, 2025-2033

Europe Plasmapheresis Machine Market Size

The Europe plasmapheresis machine market size was valued at USD 326 million in 2024 and is projected to grow from USD 355.99 million in 2025 to reach USD 719.82 million by 2033, growing at a CAGR of 9.20% during the forecast period (2025-2033).

A plasmapheresis machine is a device that extracts small volumes of blood at a time through plasmapheresis. Plasmapheresis is a procedure that involves taking blood, separating it into plasma and cells, and then returning the cells into circulation. It is done precisely to remove antibodies in the treatment of autoimmune diseases. Pheresis or apheresis is a procedure that removes blood, filters and keeps elements of it, and then restores the blood to the body. Platelets, red blood cells, white blood cells, and plasma can all be separated. During the therapy, a machine is utilised to remove small amounts of blood at a time.

There are two ways to separate the components of blood:

Centrifugation rotates the blood, splitting it into sections based on density.

Filtration: By passing the blood through a filter, the plasma is separated from the blood. During plasma exchange, the device will reject unhealthy plasma and replace it with healthy plasma from a donor. To replace harmful plasma, saline, albumin, or a combination of the two can be utilised.

Plasmapheresis/Plasmapheresis therapy is a valuable therapeutic option for individuals with severe multiple myeloma who require supportive care and have renal control dysfunction. As a result, the usage of market items grows in tandem with the frequency of various diseases and maladies. According to the data, Western Europe had the highest number of cases of myeloma for both sexes in 2016–2018.

To get more insights about this report Download Free Sample Report

Market Dynamics

Key Market Drivers

• The demand for plasmapheresis machines is expected to increase as the incidence of chronic diseases rises: In the European Region, autoimmune diseases are the third most common cause of chronic illness, affecting 5–8% of the population (NIH). Furthermore, the British Society for Immunology reports that diverse autoimmune illnesses are increasing at a rate ranging from 3% to 9% every year. One such autoimmune condition is myasthenia gravis (MG). MG is the most common neuromuscular primary ailment in the region, affecting many people. There is a greater clinical demand for plasmapheresis operations as the regular diagnosis of chronic diseases becomes increasingly common. Many patients with autoimmune, trauma and damage conditions require therapeutic plasma exchange to remove a disease factor that is circulating in the blood. As a result, the plasmapheresis machines manufacturer is expected to benefit from increased demand.

• Emerging awareness pertaining to platelet and Plasma donation: Awareness about donating plasma has increased especially after the COVID-19 pandemic as we better understood that from blood or plasma donations, a lot of lives can be saved. Still, there is a lot if requirement to create awareness but it is expected that people will become more aware of this in future which is in turn expected to increase the market growth for the plasmapheresis machine market.

Key Market Restraint

• The High Cost of Procedure: Plasmapheresis might cost anything from USD 5,000 to USD 10,000 each session in European This treatment may need to be repeated in some cases, and it will only be beneficial if individuals have medical insurance that covers such high costs. For persons from low-income households in emerging countries, this is an unaffordable option, and this, combined with unfavourable reimbursement restrictions, is expected to limit market growth during the forecast period.

Key Market Opportunities

• Technological advancements: In the coming years, technological developments in apheresis equipment will create significant demand. Growing technology developments in the healthcare profession have opened up a world of possibilities for safely treating chronic diseases that have previously defied conventional therapy. Fresenius Kabi, for example, introduced the COM.TEC C5 separation chamber, which effectively reduces separation time to less than 60 minutes.

Regional Analysis

In 2030, the Europe Plasmapheresis Machine Market is predicted to increase at a substantial rate, with a CAGR of 9.20%, reaching a total value of 552.16 million USD. Individuals with severe multiple myeloma who require supportive care and have renal control failure may benefit from plasmapheresis/plasmapheresis therapy. As a result, market item utilisation develops in lockstep with the prevalence of numerous diseases and ailments. Western Europe had the largest number of instances of myeloma for both sexes in 2016–2018, according to the data. The increasing prevalence of blood disorders is expected to boost the adoption of apheresis equipment across Europe. Blood-related diseases like sickle-cell anaemia, haemophilia, and others affect millions of people in the region.

The apheresis equipment industry in Germany is expected to increase rapidly. The presence of organisations such as the National Blood Centre and the German Red Cross Blood Transfusion Services, among others, tasked with collecting, storing, testing, and distributing blood, aids device adoption. These organisations seek to raise blood donor awareness and increase the number of blood transfusion procedures performed across the country. Furthermore, the expanding older population, which is more susceptible to blood-related illnesses, will boost the size of the German apheresis equipment market.

For the first time in almost 20 years, citizens in the United Kingdom were allowed to give blood plasma for medical purposes on April 7. The plasma, which will be used to make immunoglobulins, is being collected at 14 sites as part of a three-month experiment by NHS Blood and Transplant (NHSBT). For patients, this is a watershed moment. Immunoglobulin (antibody-based) therapy can save lives in people whose immune systems aren't performing properly due to genetic abnormalities or cancer treatment.

Segmental Analysis

The Europe plasmapheresis machine market size is segmented into type, application, end-user, and geographic segments.

Multicomponent Collection Systems (MCCS) is a form of the improved plasma collection system that catches various components of human blood during donation. It is commonly mixed with plasma and other components such as serum, RBCs, and leukocytes. Although some definitions determine multi-component collection as a technique that results in two different blood components, the vast majority of research publications written by scientists worldwide define multicomponent apheresis as a process that results in the collection of two or more identical or distinct blood components. These multicomponent collections typically use the same centrifugation procedures used for collecting each component individually under various circumstances.

Plasmapheresis is an extracorporeal therapy process because it involves the removal, treatment, return, and exchange of blood plasma/its components from and to the blood circulation. Extracorporeal refers to a medical procedure that is conducted outside of the body. The rising autoimmune disorders, such as thrombotic thrombocytopenic purpura, Goodpasture's syndrome, lupus, Guillain-Barre syndrome, myasthenia gravis, and other chronic illnesses, government reimbursement programs in developed countries, and rising demand for plasma-derived medicines are driving the growth of the extracorporeal therapy segment.

Due to the recent spike in the COVID-19 pandemic, the hospitals and clinics segment is likely to gain the most market share. This is primarily due to the increased frequency of therapeutic plasma exchange operations and increased plasma and blood component donations due to COVID-19 infection. Hospitals with in-house transfusion facilities are predicted to improve the most during the forecast period.

Impact of Covid-19

COVID Impact: During COVID-19, supply chain interruptions hampered the trade, causing a lack of raw materials for producers and a delay in delivering finished items in the form of blind bolts to customers. As official prohibitions around the world have been lifted, demand for blind bolts has already begun to rebound to pre-pandemic levels.

List of key players in Europe Plasmapheresis Machine Market

1. Fresenius SE & Co. KGaA
2. Braun Melsungen AG
3. Cerus Corporation
4. Haemonetics Corporation
5. Asahi Kasei Medical Co., Ltd
6. Charles River Laboratories International, Inc.

To get more findings about this report Download Market Share

Recent Developments

• To improve quality and compliance and increase productivity in plasma collection centres, Haemonetics offers the new NexSys PCS plasmapheresis system. Its open design empowers bidirectional connectivity to donor management systems, facilitating automated collection process programming and automated end-of-process documentation.